Literature DB >> 8803903

Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development.

R Fox1.   

Abstract

A wide variety of mechanisms of anti-rheumatic action have been proposed for anti-malarial agents. The molecular actions of chloroquine have been most thoroughly studied in vitro and in vivo, but it is likely that hydroxychloroquine works by a similar mechanism. Both agents are weak diprotic bases that can pass through the lipid cell membrane and preferentially concentrate in acidic cyto-plasmic vesicles. The resulting slight elevation of pH within these vesicles in macrophages or other antigen-presenting cells may influence the immune response to autoantigens. We hypothesize that anti-malarial agents influence the association of autoantigenic peptides with class II MHC molecules in the compartment for peptide loading and/or the subsequent processing and transport of the peptide-MHC complex to the cell membrane. This model of anti-malarial action provides a method to test additional drugs for their ability to modulate the immune response.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8803903

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  30 in total

Review 1.  The role of antimalarial agents in the treatment of SLE and lupus nephritis.

Authors:  Senq-J Lee; Earl Silverman; Joanne M Bargman
Journal:  Nat Rev Nephrol       Date:  2011-10-18       Impact factor: 28.314

Review 2.  Dendritic cells: potential triggers of autoimmunity and targets for therapy.

Authors:  J A Hardin
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

3.  Signaling of chloroquine-induced stress in the yeast Saccharomyces cerevisiae requires the Hog1 and Slt2 mitogen-activated protein kinase pathways.

Authors:  Shivani Baranwal; Gajendra Kumar Azad; Vikash Singh; Raghuvir S Tomar
Journal:  Antimicrob Agents Chemother       Date:  2014-07-14       Impact factor: 5.191

Review 4.  Systemic lupus erythematosus: Diagnosis and clinical management.

Authors:  Andrea Fava; Michelle Petri
Journal:  J Autoimmun       Date:  2018-11-16       Impact factor: 7.094

Review 5.  Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus.

Authors:  Laurie S Davis; Andreas M Reimold
Journal:  Rheumatology (Oxford)       Date:  2017-04-01       Impact factor: 7.580

Review 6.  The non-haemostatic role of platelets in systemic lupus erythematosus.

Authors:  Petrus Linge; Paul R Fortin; Christian Lood; Anders A Bengtsson; Eric Boilard
Journal:  Nat Rev Rheumatol       Date:  2018-03-21       Impact factor: 20.543

7.  Scavenging nucleic acid debris to combat autoimmunity and infectious disease.

Authors:  Eda K Holl; Kara L Shumansky; Luke B Borst; Angela D Burnette; Christopher J Sample; Elizabeth A Ramsburg; Bruce A Sullenger
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-15       Impact factor: 11.205

8.  Increased plasma myeloperoxidase levels in systemic lupus erythematosus.

Authors:  Rosa Weiss Telles; Gilda Aparecida Ferreira; Neusa Pereira da Silva; Emilia Inoue Sato
Journal:  Rheumatol Int       Date:  2009-07-29       Impact factor: 2.631

Review 9.  Pharmacotherapy Pearls in Rheumatology for the Care of Older Adult Patients: Focus on Oral Disease-Modifying Antirheumatic Drugs and the Newest Small Molecule Inhibitors.

Authors:  Blas Y Betancourt; Ann Biehl; James D Katz; Ananta Subedi
Journal:  Rheum Dis Clin North Am       Date:  2018-06-12       Impact factor: 2.670

Review 10.  A bibliometric review of drug repurposing.

Authors:  Nancy C Baker; Sean Ekins; Antony J Williams; Alexander Tropsha
Journal:  Drug Discov Today       Date:  2018-01-09       Impact factor: 7.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.